BriaCell Therapeutics Corp. BCTX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
59/100
Moderate

Ranked against 712 peers in Biotechnology

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system … Full BCTX analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 99.0th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.15), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where BCTX ranks in Biotechnology

BriaCell Therapeutics Corp. ranks #120 of 713 scored companies in Biotechnology by moat score — the top 17%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
116 Phio Pharmaceuticals Corp. PHIO 60/100 Moderate
117 Climb Bio, Inc. CLYM 59/100 Moderate
118 Ascentage Pharma Group Internat AAPG 59/100 Moderate
119 Arrowhead Pharmaceuticals, Inc. ARWR 59/100 Moderate
120 BriaCell Therapeutics Corp. BCTX 59/100 Moderate
121 BriaCell Therapeutics Corp. BCTXW 59/100 Moderate
122 Day One Biopharmaceuticals, Inc DAWN 59/100 Moderate
123 ImmunityBio, Inc. IBRX 59/100 Moderate
124 Achilles Therapeutics plc ACHL 58/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How BCTX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 77 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 30 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BCTX's moat

What is BriaCell Therapeutics Corp.'s moat score?

BriaCell Therapeutics Corp. (BCTX) scores 59 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #120 of 713 scored companies in Biotechnology, the top 17%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (77/100) and its weakest is Resilience (30/100).

How does BriaCell Therapeutics Corp. compare with other Biotechnology companies?

BriaCell Therapeutics Corp. ranks #120 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Arrowhead Pharmaceuticals, Inc. (ARWR) at 59 just above it and BriaCell Therapeutics Corp. (BCTXW) at 59 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is BriaCell Therapeutics Corp. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for BriaCell Therapeutics Corp.?

The Corporate Default template measures 6 defenses, and BCTX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (77), Resilience (30), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000